VJHemOnc Podcast The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
Jul 16, 2020
Marion Subklewe, Amir Fathi, and Andrew Wei discuss emerging immunotherapies, venetoclax-based regimens, and targeted therapies in AML. They explore challenges in translating successful treatment strategies, discuss treatment options and challenges for TP53 mutated AML patients, and highlight the importance of targeted therapies. The speakers also delve into designing frontline phase three studies for older AML patients and the challenges of label expansion for emerging immunotherapies.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Introduction
00:00 • 4min
Combination Therapy for AML and Challenges in Translating Successful Treatment Strategies
04:26 • 23min
Treatment Options and Challenges for TP53 Mutated AML Patients
27:08 • 16min
Emerging Mutations and Challenges in AML Treatment
43:29 • 2min
Understanding Different Types of FUS3 Inhibitors and the Importance of Targeted Therapies
45:24 • 2min
Challenges and Considerations in Designing Frontline Phase Three Studies for Older Patients with AML
46:56 • 4min
Exploring Emerging Immunotherapies and the Challenge of Label Expansion
50:56 • 2min